Sorafenib maintenance in FLT3-ITD mutated AML after allogeneic HCT: a real-world, single-center experience

Despite allogeneic hematopoietic stem cell transplant (allo-HCT) and the development of novel FLT3 inhibitors in both induction (midostaurin) and in the relapsed/refractory setting (gilteritinib), FLT3-ITD mutated leukemia (FLT3-ITD+ AML) still represents a challenge for modern hematology. Sorafenib...

Πλήρης περιγραφή

Λεπτομέρειες βιβλιογραφικής εγγραφής

Κύριοι συγγραφείς:	Elisa Diral, Giulia Furnari, Alessandro Bruno, Raffaella Greco, Daniela Clerici, Sarah Marktel, Francesca Farina, Sara Mastaglio, Luca Vago, Simona Piemontese, Jacopo Peccatori, Consuelo Corti, Massimo Bernardi, Fabio Ciceri, Maria Teresa Lupo-Stanghellini
Μορφή:	Artigo
Γλώσσα:	Inglês
Έκδοση:	Frontiers Media S.A. 2024-06-01
Σειρά:	Frontiers in Oncology
Θέματα:	sorafenib maintenance allogeneic stem cell transplantation FLT3 ITD acute myeloid leukemia
Διαθέσιμο Online:	https://www.frontiersin.org/articles/10.3389/fonc.2024.1391743/full
Ετικέτες:	Προσθήκη ετικέτας Δεν υπάρχουν, Καταχωρήστε ετικέτα πρώτοι!